Media Newsroom of

InDevR, Inc.

2100 Central Ave (106)
Boulder, CO 80301

InDevR, Inc., is a leader in providing progressive analytical technologies that enhance and accelerate vaccine characterization and production.

InDevR Delivers Commercial Multiplex Coronavirus SeroAssay Kit and Testing Services for Vaccine Development

InDevR Delivers Commercial Multiplex Coronavirus SeroAssay Kit and Testing Services for Vaccine Development

InDevR, Inc., a leader in novel analytical technologies that support the development and production of vaccines and biotherapeutics, announced commercial availability of its COVID-19 serology test kits. InDevR’s VaxArray Coronavirus SeroAssay leverages the Company’s established VaxArray platform to deliver a…

InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical Validation

InDevR Ships First Multiplexed COVID-19 Serology Test Kits for Clinical Validation

InDevR, Inc., a leader in progressive analytical technologies to support the development and production of vaccines and biotherapeutics, announced shipment of its first COVID-19 serology test kits this week for clinical validation. InDevR’s VaxArray Coronavirus SeroAssay is a microscale multiplexed…

510(k) Market Clearance for FluChip-8G Influenza A+B Assay

510(k) Market Clearance for FluChip-8G Influenza A+B Assay

​​​​​InDevR Inc., a leader in progressive analytical technologies, announced today that they have received 510(k) market clearance for their FluChip-8G Influenza A+B Assay from the United States Food and Drug Administration (FDA). FluChip-8G is the first cleared influenza diagnostic capable…

First Influenza-Specific Neuraminidase Test Kit

InDevR Inc. announced product release of the first ever commercial reagent kit designed explicitly for assessment of neuraminidase (NA) in influenza vaccines. The new VaxArray kit is poised to help improve influenza vaccines by empowering manufacturers with a standardized method to…

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay

InDevR Licenses Mount Sinai Influenza Antibodies for VaxArray® Neuraminidase Potency Assay

​​InDevR, a Boulder-based progressive analytical technology and life science instrumentation company today announced that it has entered into an exclusive, world-wide license agreement for monoclonal antibodies developed by scientists at the Icahn School of Medicine at Mount Sinai. The license agreement…

Login

Or using ePRNews Account

Don't have an account ? Sign Up

Register New Account

Already have an account ? Login

Reset Password

Already have an account ? Login